Managing AEs associated with bortezomib in the treatment of Waldenström's macroglobulinemia скачать в хорошем качестве

Managing AEs associated with bortezomib in the treatment of Waldenström's macroglobulinemia

Jahanzaib Khwaja, MD, FRCPath, University College London Hospitals NHS Foundation Trust, London, UK, discusses adverse events (AEs) associated with bortezomib in the treatment of Waldenström's macroglobulinemia, with reference to his study of bortezomib in patients who have failed BTK inhibitors. He mentions neurotoxicity and cytopenias as potential AEs that can be managed with dose reductions and close monitoring. This interview took place at the 12th International Workshop on Waldenström's Macroglobulinemia (IWWM-12) in Prague, Czech Republic. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.